Journal Article

Safety of Low‑Dose Quetiapine for Insomnia in Older Adults

Lee, Ashley L, Lee, Robin S, Niu, Fang, Lee, Eric A, Hui, Rita L

2025

Overview

Background and Objective Quetiapine is a Food and Drug Administration (FDA) approved second-generation antipsychotic. It is also commonly used at low dose for its sedative properties to treat insomnia in the older population. Quetiapine at standard doses has been associated with increased risk of cerebrovascular events, cognitive decline, and mortality in patients with dementia, especially within older adults. However, there are limited data describing its safety at lower doses, especially for the treatment of insomnia in older adults. This study aims to compare the safety of low-dose quetiapine versus trazodone or mirtazapine for insomnia in older adults in the USA. Methods This was a retrospective cohort study that included patients aged 65 years or older who started low-dose quetiapine, trazodone, or mirtazapine for the treatment of insomnia from October 2018 to September 2021. The primary outcome was allcause mortality and secondary outcomes included new incidences of stroke or transient ischemic attack, dementia, and falls With or without traumatic fractures. They were identified from electronic medical records using ICD-10-CM clinical diagnosis codes. Eligible patients were followed from the initiation of the drug until death, end of target drug exposure or escalation of dose, end of health plan membership, or 30 September 30 2022, whichever came first. Patients initiated mirtazapine or trazodone were matched to each patient who initiated quetiapine at a 4:1 ratio using propensity score matching method. Results We included 375 patients initiated on low-dose quetiapine, who were matched to 1500 patients started on trazodone and 1500 patients started on mirtazapine. Comparing patients who received quetiapine with trazodone, the quetiapine group had an increased risk of mortality (hazard ratio (HR) 3.1, 95% confidence interval (CI) 1.2-8.1; P<0.05), dementia (HR 8.1, 95% CI 4.1-15.8; P<0.05), and falls (HR 2.8, 95% CI 1.4-5.3; P<0.05). When comparing quetiapine with mirtazapine, quetiapine group had an increased risk of dementia (HR 7.1, 95% CI 3.5-14.4; Р < 0.05). No significant differences were detected in other outcomes. Conclusions Caution should be taken in practice when using low-dose quetiapine for insomnia in older adults. It is associated with significantly higher rates of mortality, dementia, and falls when compared with trazodone and a higher dementia rate when compared with mirtazapine.

• Publisher: Springer Nature B.V
• Subject: Antipsychotics / Drug dosages / Electronic health records / Insomnia / Mortality / Older people / Pharmacists / Psychotropic drugs / Transient ischemic attack